Acute Myeloid Leukemia Clinical Trial
Official title:
Study to Evaluate the Anti-emetic Effect of Aprepitant as an add-on Therapy in Children and Adolescents Receiving AML Remission Induction Chemotherapy: An Investigator-initiated, Randomized, Open Label Trial
The purpose of the study is to find out the efficacy of an anti-emetic drug, Aprepitant as
an add-on therapy to prevent vomiting in children and adolescents receiving chemotherapy for
leukemia (AML).
Children and adolescents admitted with confirmed diagnosis of AML will be assessed for
eligibility criteria and enrolled in the study. Then they will be divided (randomized) into
experimental and control groups.
Experimental group will receive Aprepitant capsules 1 h prior to chemotherapy on days 1-3 in
addition to ondansetron. Patients will be required to swallow the whole capsule and opening
of capsule will not be permitted. All three doses will be administered under supervision.
Control group will receive ondansetron (0.15 mg/kg) as an intravenous bolus 30 minutes
before chemotherapy followed by every 8 hourly for 8 days. Metoclopramide will be used as a
rescue agent.
The data will be collected from each patient in a proforma from day 1 to day 13 of
chemotherapy. A Diary will be maintained for nausea and vomiting record.
Edmonton's symptom assessment criterion will be used in the diary for assessing severity of
nausea. The NCI guidelines will be used to assess the severity of vomiting based on the data
provided by the patient in the diary.
A modified intention-to-treat population (patients who receive chemotherapy, take one or
more doses of study drug, and have one or more post treatment measurements) will be used for
efficacy analysis. Proportion of patients with complete response will be compared between
patients with or without aprepitant.
Children and adolescents admitted with confirmed diagnosis of AML will be assessed for
eligibility criteria and enrolled in the study. Subjects will be randomized into
experimental and control groups using table of random numbers generated by
computer.Experimental group will receive aprepitant capsules as an add-on therapy (Apretero;
Hetero Laboratories, India) 1 h prior to chemotherapy on days 1-3 in addition to
ondansetron.
The dose of aprepitant will be as per our previous study based on weight groups'
- Weight 15-40 kg : Aprepitant 80 mg on days 1-3
- Weight > 41kg: Aprepitant 125 mg on day 1 followed by 80 mg on days 2-3 Patients will
be required to swallow the whole capsule and opening of capsule will not be permitted.
All three doses will be administered under supervision by the sister allocated. Control
group will receive ondansetron (0.15 mg/kg) as an intravenous bolus 30 minutes before
chemotherapy followed by every 8 hourly. Metoclopramide will be used as a rescue agent.
The data will be collected from each patient in a proforma from day 1 to day 13 of
chemotherapy by the investigator during his/her stay as in-patient in the hospital. The
Proforma will contain different items dealing with demographic and clinical characteristic
of the subjects.A Diary will be maintained for nausea and vomiting record. It will help in
collecting data regarding nausea, vomiting along with some additional variables like-
chemotherapy related toxicities, requirement of any rescue medication.
The subjects will be given the diary for symptom assessment on day 1 and it will be filled
up under the supervision of the investigator on day 1 and day 2 of chemotherapy. The diary
will be given to the subjects on day 3 of the chemotherapy to record all the events
(incidence and severity of nausea, vomiting, requirement of rescue medication and other
toxicities).
Edmonton's symptom assessment criterion will be used in the diary for assessing severity of
nausea. The NCI guidelines will be used to assess the severity of vomiting based on the data
provided by the patient in the diary.Patients/attendant's will be explained about the
filling of the diary and will maintain it for recording of vomiting under the investigator's
supervision.
A modified intention-to-treat population (patients who receive chemotherapy, take one or
more doses of study drug, and have one or more post treatment measurements) will be used for
efficacy analysis.Proportion of patients with CR will be compared between patients with or
without aprepitant.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
| Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
| Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
| Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
| Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
| Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
| Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
| Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
| Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
| Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
| Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
| Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
| Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
| Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
| Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
| Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |